Unique opportunity to acquire a rapidly scaling, fully remote telemedicine and digital prescription, GDPR-compliant platform operating under the EU cross-border framework. The business connects over 20,000 patients with licensed doctors and pharmacies in Germany
Licence(s) Held
Operates under EU cross-border telemedicine framework (Physicians licensed in Germany & Poland). GDPR-compliant platform. No direct cannabis handling license required.
Listing Details
Cyprus-based company operates a fully digital telemedicine platform, enabling remote consultations and digital prescriptions
Launched in 2024, the platform has served approximately 20,000 patients and processed over 6,500 prescriptions per month
Focused on deep process optimization to ensure scalability before launching targeted marketing campaigns, including Facebook advertising and affiliate marketing, and continues to implement new features to enhance user experience
Profitable business with margins exceeding 60%, a current revenue run rate of ~€140,000 per month, and a forecasted €1.5M by year-end, reflecting ~20% annual growth
Income is generated through patient appointment bookings, marketing services for pharmacies, partnerships with leading producers, and white-label product offerings.
Operates efficiently with ~12 staff/freelancers, leveraging front-end and back-end freelance specialists
Automated workflows reduce doctor consultation time by 90%, and the platform supports white-label functionality for rapid B2B expansion
Projected annual growth of 15–20% is driven by rising patient demand and recent liberalization of the German cannabis market
Seeking full sale and includes the going concern business, intellectual property, brand, patient database, and software codebase
Currency: USD
Target Price / Revenue: TBD
Target Price / EBITDA: TBD
